155 related articles for article (PubMed ID: 26945442)
1. Emerging Role of Nestin as an Angiogenesis and Cancer Stem Cell Marker in Epithelial Ovarian Cancer: Immunohistochemical Study.
Osman WM; Shash LS; Ahmed NS
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):571-580. PubMed ID: 26945442
[TBL] [Abstract][Full Text] [Related]
2. Proliferation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor PDGF-B.
Czekierdowska S; Stachowicz N; Chróściel M; Czekierdowski A
Ginekol Pol; 2017; 88(3):120-128. PubMed ID: 28397199
[TBL] [Abstract][Full Text] [Related]
3. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
Wang X; Zhu Q; Lin Y; Wu L; Wu X; Wang K; He Q; Xu C; Wan X; Wang X
Br J Cancer; 2017 Oct; 117(9):1371-1382. PubMed ID: 28898232
[TBL] [Abstract][Full Text] [Related]
6. Expression of Nestin and CD133 in serous ovarian carcinoma.
Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
9. Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).
Ren J; Jin W; Gao YE; Zhang Y; Zhang X; Zhao D; Ma H; Li Z; Wang J; Xiao L; Liu R; Chen Y; Qian J; Niu L; Wei H; Liu Y
Curr Pharm Des; 2014; 20(11):1904-16. PubMed ID: 23888957
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of TEM7 and nestin expression in women with advanced high grade serous ovarian cancer.
Czekierdowski A; Stachowicz N; Czekierdowska S; Łoziński T; Gurynowicz G; Kluz T
Ginekol Pol; 2018; 89(3):135-141. PubMed ID: 29664548
[TBL] [Abstract][Full Text] [Related]
11. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
12. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
[TBL] [Abstract][Full Text] [Related]
13. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
14. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer.
Szubert S; Szpurek D; Moszynski R; Nowicki M; Frankowski A; Sajdak S; Michalak S
J Cancer Res Clin Oncol; 2014 Mar; 140(3):361-9. PubMed ID: 24374756
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
17. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis.
Zhao L; Li J; Liu M; Zhou H; Zou H; Wei Y; Sun K; Li G; Li S; Pang L
Future Oncol; 2017 Dec; 13(28):2555-2570. PubMed ID: 29168665
[TBL] [Abstract][Full Text] [Related]
19. Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer.
Cybulski M; Jarosz B; Nowakowski A; Jeleniewicz W; Seroczyński P; Mazurek-Kociubowska M
Gynecol Oncol; 2012 Oct; 127(1):217-22. PubMed ID: 22772062
[TBL] [Abstract][Full Text] [Related]
20. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction.
Semaan A; Munkarah AR; Arabi H; Bandyopadhyay S; Seward S; Kumar S; Qazi A; Hussein Y; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2011 Apr; 121(1):181-6. PubMed ID: 21167567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
